The FDA has approved Leqembi Iqlik, a subcutaneous, autoinjector formulation for maintenance dosing in people with early Alzheimer's disease ...

September is World Alzheimer’s Month, and the global Alzheimer’s disease community is looking to raise awareness and combat ...

The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that ...

Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. “Cassava Sciences is a ...

The U.S. Food and Drug Administration (FDA) has approved BrainSee, Darmiyan’s software for predicting the likelihood that a person with mild cognitive impairment (MCI) will progress to Alzheimer’s ...

If you have a loved one who’s been diagnosed with Alzheimer’s disease, what’s the chance that they’ll walk away from the safety of their home? According to the Alzheimer’s Association, anyone with ...